GlassScriptPhysician profile
Garrett W Walker
NPI 1174147318
$1,118.57
in general payments reported to CMS, 2019-2025
23 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.01 · 2023: $64.27 · 2024: $507 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $250.12 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $189.19 | 2023-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $81.83 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Saluda Medical Americas, INC. | $77.82 | 2025 | Evoke |
| Astellas Pharma US INC | $47.51 | 2025 | Veozah |
| Amgen INC. | $46.43 | 2022-2025 | Otezla, Repatha, Otezla |
| Neos Therapeutics, LP | $43.75 | 2023-2024 | Adzenys Xr-Odt |
| Bayer Healthcare Pharmaceuticals INC. | $42.62 | 2024 | |
| Axsome Therapeutics, INC. | $37.85 | 2023-2024 | Auvelity |
| Pfizer INC. | $37.59 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $35.75 | 2024-2025 | Capvaxive, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.96 | 2024 | Jardiance |
| Seqirus USA INC | $27.63 | 2025 | Flucelvax, Fluad |
| Boston Scientific Corporation | $23.46 | 2025 | Watchman Flx |
| Hologic Sales and Service, LLC | $22.15 | 2024 | Aptima, Thinprep 2000 Processor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.10 | 2025 | Spravato |
| Dexcom, INC. | $17.67 | 2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $16.91 | 2025 | Unithroid |
| Noven Therapeutics, LLC | $15.96 | 2024 | Xelstrym |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2024 | Airsupra |
| Exact Sciences Corporation | $14.07 | 2025 | The Cologuard Plus Collection Kit |
| Insulet Corporation | $13.98 | 2025 | Omnipod |
| Biogen, INC. | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.